Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'

Go back to Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
CYTOKINETICS (NASDAQ: CYTK) Delayed: 80.01 +0.84 (1.06%)
Previous Close $79.17    52 Week High $13.18 
Open $78.99    52 Week Low $6.00 
Day High $80.40    P/E N/A 
Day Low $78.27    EPS $-1.24 
Volume 1,859,154